DUBLIN--(BUSINESS WIRE)--The "2018 Peptic Ulcers Drug Development- Pipeline Analysis Report" report has been added to ResearchAndMarkets.com's offering.
At least 10% of the US population suffers from peptic ulcers in a lifetime. The market value is estimated to be around $500 million in 2020.
Over 20 companies and universities are focusing on developing treatment options for Peptic Ulcers.
This report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials. Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Peptic Ulcers pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Peptic Ulcers pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
- Balto Therapeutics LLC
- Boryung Pharmaceutical Co. Ltd
- Catalent Inc.
- CJ HealthCare Corp.
- Daewoong Pharmaceutical Co. Ltd
- Infectex Ltd
- Kukje Pharmaceutical Company
- Pfizer Inc.
- Pharmaking Ltd
- PT. Dexa Medica
- RaQualia Pharma Inc.
- Recce Pharmaceuticals Ltd
- Sequella Inc
- Shandong Luoxin Pharmaceutical Group Stock Co. Ltd.
- Sihuan Pharmaceutical Holdings Group
- Sinil Pharmaceutical Co. Ltd
- Xuanzhu Pharma Co Ltd
Key Topics Covered
1 Table of Contents
2 Peptic Ulcers Pipeline Analysis
3 Peptic Ulcers - Company-wise Pipeline Analysis
4 Peptic Ulcers R&D Pipeline Snapshots
5 Recent Developments in Peptic Ulcers Pipeline
For more information about this report visit https://www.researchandmarkets.com/research/vds2lb/2018_pipeline?w=4